SA
SANA logo
Sana Biotechnology, Inc.(SANA)
Closing price · checked 3:56 AM ETAbout this dataData status
$1.88▲0.00 (0.00%)
Extended:$1.88+0.00 (+0.00%)· 3:56 AM ET

Sana Biotechnology, Inc. focuses on developing engineered cell therapies for various diseases, including cancer and genetic disorders. The company aims to leverage its proprietary technology platforms to create durable and potentially curative treatments, setting it apart in the competitive landscape of biotechnology.

HealthcareBiotechnologylow - The company currently has no revenue and relies on external funding, leading to high fixed costs associated with R&D without corresponding revenue generation.

Business Overview

01Research and development collaborations with pharmaceutical companies (estimated 100%)

Sana Biotechnology primarily generates revenue through partnerships and collaborations with larger pharmaceutical firms, focusing on advancing its proprietary cell therapy technologies. The company has a strong pipeline of product candidates, which may provide significant pricing power once commercialized.

What Moves the Stock

Progress in clinical trials for lead candidates, particularly the SAN-100 program targeting genetic disorders

Partnership announcements with major pharmaceutical companies

Regulatory approvals for investigational therapies

Updates on funding rounds or collaborations that enhance liquidity

Watch on Earnings
Clinical trial milestones achievedPartnership revenue generationCash burn rate

Risk Factors

Regulatory changes impacting drug approval processes

Technological disruption from competing therapies or platforms

Emergence of alternative therapies that could outperform Sana's offerings

Increased competition from larger biotech firms with more resources

High cash burn rate leading to potential liquidity issues

Dependence on external funding for ongoing operations

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - The biotechnology sector is generally less sensitive to economic cycles, as demand for healthcare remains relatively stable regardless of economic conditions.

Interest Rates

Moderate - Rising interest rates could increase the cost of capital for funding R&D, impacting the company's ability to finance its operations and growth initiatives.

Credit

minimal - The company has a manageable debt-to-equity ratio of 0.63, indicating limited reliance on credit for operations.

Live Conditions
S&P 500 FuturesDow Jones FuturesRussell 2000 Futures

Profile

growth - Investors are likely attracted to the potential for high returns from successful therapies.

high - The stock has shown significant volatility, with a 1-year return of 47.3% and a 3-month return of -21.9%.

Key Metrics to Watch
Clinical trial success rates for SAN-100
Cash runway (months until funding is needed)
Partnership announcements and their financial terms
Market sentiment towards biotechnology sector
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.